Abstract
Supplementary Table S1. Representativeness of study participants Supplementary Table S2. Averagea change from baseline in prespecified key EORTC QLQ-C30 and QLQ-LC13 scale scores over all timepoints (MMRM). Supplementary Figure S1. Patient-reported outcome assessment schedules in FLAURA2. Supplementary Figure S2. Patient-reported outcome questionnaire compliance rates. Supplementary Figure S3. Proportion of patients with different A, frequency and B, severity scores for the additional prespecified PRO-CTCAE symptoms at different timepoints. Weeks 13 (3.0 months), 37 (8.5 months), and 97 (22.3 months) of the PRO-CTCAE assessments represent the closest available timepoints to the end of the induction, median pemetrexed maintenance and median osimertinib treatment, respectively, for the osimertinib plus chemotherapy arm. Conditional branching logic was employed for PRO-CTCAE symptom terms that have two or more attributes, thereby reducing the sample size from frequency to severity for symptoms. PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events